FIGURE 13. Random-effects meta-analysis: NPI at 12 weeks (mean change from baseline): donepezil [all dosages (all are 10 mg/day)] vs placebo.

FIGURE 13Random-effects meta-analysis: NPI at 12 weeks (mean change from baseline): donepezil [all dosages (all are 10 mg/day)] vs placebo

a, Score inverted from published figure to reflect usual direction of NPI; b, WMD and error bars provided in publication – SE estimated on assumption that error bars represent 95% CIs.

From: 3, Assessment of clinical effectiveness

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.